Analysts Set Expectations for Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Tourmaline Bio in a report issued on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.85) per share for the year, down from their previous estimate of ($3.15). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Tourmaline Bio’s FY2026 earnings at ($3.76) EPS.

Tourmaline Bio (NASDAQ:TRML) last issued its earnings results on Wednesday, August 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.04.

A number of other brokerages also recently commented on TRML. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Tourmaline Bio in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Tourmaline Bio in a research report on Monday, May 5th. Finally, Chardan Capital reiterated a “buy” rating and issued a $70.00 price objective on shares of Tourmaline Bio in a research report on Thursday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $50.14.

Tourmaline Bio Trading Up 0.8%

Shares of Tourmaline Bio stock opened at $22.57 on Monday. The stock has a market capitalization of $579.71 million, a price-to-earnings ratio of -6.58 and a beta of 2.04. Tourmaline Bio has a twelve month low of $11.56 and a twelve month high of $29.79. The business’s 50 day simple moving average is $19.05 and its 200-day simple moving average is $16.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TRML. BNP Paribas Financial Markets grew its position in Tourmaline Bio by 34.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company’s stock valued at $34,000 after buying an additional 535 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Tourmaline Bio by 35.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company’s stock worth $51,000 after acquiring an additional 846 shares during the period. Invesco Ltd. lifted its stake in shares of Tourmaline Bio by 10.8% in the 4th quarter. Invesco Ltd. now owns 12,155 shares of the company’s stock worth $247,000 after acquiring an additional 1,181 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company’s stock valued at $33,000 after acquiring an additional 1,232 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Tourmaline Bio by 3.9% during the first quarter. SG Americas Securities LLC now owns 36,180 shares of the company’s stock valued at $550,000 after acquiring an additional 1,368 shares during the period. 91.89% of the stock is owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.